Skip to content

Effectiveness and Implementation of a Mindfulness Intervention for Depressive Symptoms Among Adults in a FQHC

Effectiveness and Implementation of a Mindfulness Intervention for Depressive Symptoms Among Low-income, Racial/Ethnic Minority Adults in a Federally Qualified Health Center

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03620721
Acronym
M-Body
Enrollment
245
Registered
2018-08-08
Start date
2019-03-01
Completion date
2023-08-30
Last updated
2023-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Symptoms, Stress, Physiological, Stress, Psychological

Brief summary

The objective of this project is to examine the clinical effectiveness of a mindfulness intervention on reducing depressive symptoms among socio-economically disadvantaged, racial/ethnic minority adults and explore factors related to implementation in a Federally Qualified Health Center (FQHC). This research will be used to develop a generalizable model for delivery of streamlined mental health interventions in community based settings that will be broadly disseminated and scalable to other populations. Black and Hispanic adults are more likely than those who are White to receive depression treatment in primary care, where antidepressants are the most commonly offered treatment. However, Black and Hispanic adults are less likely than Whites to find antidepressants acceptable. A mindfulness depression intervention provided within primary care may be more accessible and acceptable for low-income, racial/ethnic minority individuals, a severely underserved population. The investigators will conduct a randomized controlled trial to test the clinical effectiveness of a mindfulness intervention (M-Body) on reducing depressive symptoms, compared to usual care, among low-income racial/ethnic minority adults in a FQHC. The M-Body intervention is based on Mindfulness Based Stress Reduction and has been tailored for the FQHC setting and patient population. Adults (N=254) with depressive symptoms will be recruited from a FQHC in the Chicago, IL area that serves majority racial/ethnic minority individuals (90%) living at or below the poverty line (74%). Half of the patients will be randomized to the M-Body intervention arm where they will receive 8-weeks of mindfulness training led by FQHC staff and the other half will be randomized to usual care. Information on factors relevant to implementation of the intervention in the FQHC will be obtained by convening a series of workgroups and individual interviews with FQHC staff, executive leadership and community stakeholders. Specific Aims: 1) Determine the effectiveness of M-Body on reducing depressive symptoms compared to enhanced usual care for racial/ethnic minority adults in a FQHC; 2) Explore potential mediators (stress related biomarkers, mindfulness) and moderators (age, personal, social, environmental stressors) of the intervention's effect; 3) Conduct a broad assessment of organizational and individual agency factors related to preparation and implementation of the M-Body intervention in a FQHC using a mixed methods approach.

Interventions

BEHAVIORALmindfulness

8-week mindfulness based group intervention

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18-65 years old * mild to severe depressive symptoms (Patient Health Questionnaire-9, PHQ-9, total score ≥ 5) * English speaking

Exclusion criteria

* PHQ-9 total score \<5 * past 30-day suicidal ideation * current, regular practice of meditation (≥ 4 per week)

Design outcomes

Primary

MeasureTime frameDescription
Depressive Symptoms6 monthsInventory of Depressive Symptoms (IDS-C), 30 items rated on a 0-3 point scale, total scores range from 0-84

Secondary

MeasureTime frameDescription
Anxiety6 monthsGeneralized Anxiety Disorder (GAD-7), 7 items, rated on a 0-3 point scale
Anger6 monthsAnger Self-Report Questionnaire (ASRQ), 30 items rated on a 1-6 point scale

Other

MeasureTime frameDescription
Self-Compassion6-monthsSelf Compassion Scale (SCS), 26 items rated on a 1-5 point scale
Affective Dysregulation6 monthsDifficulties in Emotion Regulation Scale (DERS), 36 items rated on a 1-5 point scale
Negative Thinking6 monthsReflection and Rumination Questionnaire (RRQ), 24 items rated on a 1-5 point scale
Social FunctioningBaselineSocial Problems Questionnaire (SPQ), 33 items rated on a 0-3 point scale
Self-reported Stress6 monthsPerceived Stress Scale (PSS), 10 items rated on a 0-4 point scale
SpiritualityBaselineSpirituality Scale (SS), 8 items rated on a 1-6 point scale
Blood PressureBaseline, 8, 16, and 24 weeksRanges of blood pressure measurements (mmHg)
Inflammatory BiomarkersBaseline, 8, 16, and 24 weeksDried Blood Spot (DBS) samples will be assessed for inflammatory biomarkers (CRP, IL6, and IL8)
Race-Based StressBaseline and 8 weeksRacial and Ethnic Microaggressions Scale (REMS), 28 items rated on a 0-5 point scale
Traumatic Life Events6 monthsPTSD Checklist for DSM-5 (PCL-5) with Life Events Checklist-5 (LEC-5), 20 items rated on a 0-4 point scale with an additional 17 items checklist
Mindfulness6 monthsFive Facet Mindfulness Questionnaire (FFMQ), 14 items rated on a 1-5 point scale
Cognitive Reactivity6 monthsCognitive Emotion Regulation Questionnaire (CERQ), 36 items rated on a 1-5 point scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026